妇科癌症精准肿瘤学试验中种族和民族少数群体个体的入组情况
该横断面综述检索ClinicalTrials.gov,纳入61项美国妇科癌症精准肿瘤学试验,比较实际入组与基于SEER和人口普查数据计算的预期入组人数。非西班牙裔白人女性总体入组比1.26(95%CI 1.20-1.32),而亚裔、非西班牙裔黑人和西班牙裔女性入组比分别为0.63(95%CI 0.41-0.86)、0.51(95%CI 0.36-0.66)和0.30(95%CI 0.23-0.36),后三者均被低估。结论认为少数种族和民族女性在精准肿瘤学试验中入组不足。
要点
- 非西班牙裔白人女性总体入组比1.26(95%CI 1.20-1.32),代表入组过多。
- 亚裔、非西班牙裔黑人和西班牙裔女性入组比分别为0.63、0.51和0.30,均低于1。
- 西班牙裔女性在所有癌症类型试验中均入组不足。
核心结论
- 非西班牙裔黑人女性、亚裔女性和西班牙裔女性在妇科癌症精准肿瘤学试验中入组不足。
- 美国针对子宫癌和宫颈癌的精准肿瘤学试验很少,而这些癌症在种族和民族少数群体中发病率和死亡率负担高。
- 未能公平入组种族和民族少数群体患者可能加剧妇科癌症结局的现有差异。
研究设计与样本
- 横断面综述,检索ClinicalTrials.gov,纳入使用肿瘤或患者基因组分子谱分析来指导治疗的美国卵巢癌、子宫癌、宫颈癌和外阴癌精准肿瘤学试验。
- 使用美国国家癌症研究所监测、流行病学和最终结果数据及美国人口普查局数据估计每种妇科癌症的癌症负担和按种族和民族划分的预期试验参与者人数。
- 计算实际与预期参与者比值,比值大于1表示入组过多;进行随机效应荟萃分析以评估各试验的相对权重。
- 共识别493项试验,其中61项符合纳入标准。
- 卵巢癌试验入组2,573例患者,子宫癌试验入组1,197例,宫颈癌试验入组162例。
主要发现
- 非西班牙裔白人女性总体入组过多(入组比1.26,95%CI 1.20-1.32),亚组分析中在所有癌症类型均入组过多。
- 亚裔女性总体入组不足(入组比0.63,95%CI 0.41-0.86)。
- 非西班牙裔黑人女性总体入组不足(入组比0.51,95%CI 0.36-0.66)。
- 西班牙裔女性总体入组不足(入组比0.30,95%CI 0.23-0.36)。
- 亚组分析中,亚裔女性和非西班牙裔黑人女性在卵巢癌和子宫癌试验中入组不足,西班牙裔女性在所有癌症类型试验中入组不足。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize whether enrollment patterns in precision oncology clinical trials for gynecologic cancers reflect the racial and ethnic diversity of patients with gynecologic cancers in the United States. METHODS: ClinicalTrials.gov was queried to perform this cross-sectional review. We included precision oncology trials -defined as trials using molecular profiling of a tumor or the patient genome to identify targetable alterations to guide treatment-of ovarian, uterine, cervical, and vulvar cancers in the United States. National Cancer Institute Surveillance, Epidemiology, and End Results and United States Census Bureau data were used to estimate cancer burden and the expected number of trial participants by race and ethnicity for each gynecologic cancer. The ratio of actual-to-expected participants was calculated. A ratio greater than 1 signified overenrollment. A random effects meta-analysis was performed to assess the relative weights of individual trials. RESULTS: We identified 493 trials, 61 of which met inclusion criteria. There were 2,573 patients enrolled in ovarian cancer trials, 1,197 in uterine cancer trials and 162 in cervical cancer trials. Non-Hispanic White women were overrepresented overall (enrollment ratio 1.26, 95% CI 1.20-1.32) and across all cancer types on subgroup analysis. Asian women, non-Hispanic Black women, and Hispanic women were underrepresented overall (enrollment ratios 0.63, 95% CI 0.41-0.86; 0.51, 95% CI 0.36-0.66 and 0.30, 95% CI 0.23-0.36, respectively). In subgroup analyses, Asian women and non-Hispanic Black women were underrepresented in ovarian and uterine cancer trials and Hispanic women were underrepresented across all cancer types. CONCLUSION: Non-Hispanic Black women, Asian women, and Hispanic women with gynecologic cancers are underrepresented in precision oncology trials. Few U.S.-based precision oncology trials exist for uterine and cervical cancers, which have a high burden of morbidity and mortality among racial and ethnic minority groups. Failure to equitably enroll patients who belong to racial and ethnic minority groups may perpetuate existing disparities in gynecologic cancer outcomes.
引用
- Mattei LH, Robb L, Banning K, et al. Enrollment of Individuals From Racial and Ethnic Minority Groups in Gynecologic Cancer Precision Oncology Trials. Obstet Gynecol. 2022. PMID: 36075065. doi:10.1097/AOG.0000000000004917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。